JPH06113828A - Additive composition for serum-free medium - Google Patents
Additive composition for serum-free mediumInfo
- Publication number
- JPH06113828A JPH06113828A JP4270531A JP27053192A JPH06113828A JP H06113828 A JPH06113828 A JP H06113828A JP 4270531 A JP4270531 A JP 4270531A JP 27053192 A JP27053192 A JP 27053192A JP H06113828 A JPH06113828 A JP H06113828A
- Authority
- JP
- Japan
- Prior art keywords
- serum
- fraction
- additive composition
- medium
- free medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012679 serum free medium Substances 0.000 title claims abstract description 11
- 239000000203 mixture Substances 0.000 title claims abstract description 8
- 239000000654 additive Substances 0.000 title claims abstract description 7
- 230000000996 additive effect Effects 0.000 title claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 21
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 21
- 229940109850 royal jelly Drugs 0.000 claims abstract description 17
- 238000004113 cell culture Methods 0.000 claims description 10
- 230000010261 cell growth Effects 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 12
- 239000002609 medium Substances 0.000 abstract description 11
- 238000012258 culturing Methods 0.000 abstract description 4
- 238000005342 ion exchange Methods 0.000 abstract description 3
- 235000000346 sugar Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 235000001014 amino acid Nutrition 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 239000006143 cell culture medium Substances 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 150000008163 sugars Chemical class 0.000 abstract 1
- 235000018102 proteins Nutrition 0.000 description 19
- 230000001737 promoting effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 8
- 101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 5
- 210000004102 animal cell Anatomy 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010828 elution Methods 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003102 growth factor Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004017 serum-free culture medium Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 229960001471 sodium selenite Drugs 0.000 description 1
- 235000015921 sodium selenite Nutrition 0.000 description 1
- 239000011781 sodium selenite Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Landscapes
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
【0001】[0001]
【産業上の利用分野】この発明は、例えば動物細胞培養
のための無血清培地に添加されることにより、細胞増殖
促進効果等を示す無血清培地用添加組成物に関するもの
である。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an additive composition for a serum-free medium which exhibits a cell growth promoting effect and the like when added to a serum-free medium for culturing animal cells, for example.
【0002】[0002]
【従来の技術】従来、動物細胞による有用物質生産の際
には、生産性を上げるために10%程度の動物血清を添
加した培地が使用されてきた。2. Description of the Related Art Conventionally, in the production of useful substances by animal cells, a medium supplemented with about 10% of animal serum has been used in order to improve productivity.
【0003】[0003]
【発明が解決しようとする課題】ところが、このような
培地中には高濃度の血清由来の蛋白質が含まれてしまう
ために、得られる生成液から有用物質を取り出すための
精製法が複雑となる。しかも、動物血清は製造ロットに
よる品質の差が大きく、必ずしも安定供給されておら
ず、高価でもあることから、動物細胞による有用物質の
生産コストを上昇させる要因にもなっているという問題
があった。However, since such a medium contains a high concentration of protein derived from serum, the purification method for taking out a useful substance from the obtained product solution becomes complicated. . Moreover, animal serum has a large difference in quality depending on the production lot, is not always stably supplied, and is expensive, which causes a problem of increasing the production cost of useful substances by animal cells. .
【0004】この発明はこのような従来の問題に着目し
てなされたものであって、その目的は、優れた細胞増殖
促進活性等の細胞培養活性を発揮して効率的な細胞培養
ができると共に、生産された有用物質の分離、精製を容
易に行うことができ、しかも低コストで安定した品質の
ものを供給可能な無血清培地用添加組成物を提供するこ
とにある。The present invention has been made in view of such conventional problems, and an object thereof is to exert an excellent cell culture activity such as a cell growth promoting activity and enable efficient cell culture. Another object of the present invention is to provide an additive composition for serum-free medium, which can easily separate and purify the produced useful substance, and can supply stable quality at low cost.
【0005】[0005]
【課題を解決するための手段】上記目的を達成するため
に、この発明の細胞培養のための無血清培地用添加組成
物はローヤルゼリー由来の蛋白質を含有することを特徴
とする。To achieve the above object, the additive composition for serum-free medium for cell culture of the present invention is characterized by containing a protein derived from royal jelly.
【0006】次に、この発明についてさらに詳細に説明
する。ローヤルゼリーは蜜蜂が作り出すもので、女王蜂
はこのローヤルゼリーのみを摂取して生命を営み、膨大
な量の卵を生む。これは、ローヤルゼリーが完全食品と
いわれているように栄養豊かで多岐にわたる生理作用を
有するためである。即ち、この生理作用は抗癌作用、抗
腫瘍作用、創傷治癒促進作用、抗菌作用、抗糖尿病作
用、血流増加作用、抗動脈硬化作用、発育促進作用など
である。このことは、ローヤルゼリー中に生理活性物質
が存在していることを意味している。このような点に着
目して、ローヤルゼリーは健康食品、化粧品、医薬品等
として利用されている。Next, the present invention will be described in more detail. Royal jelly is produced by bees, and the queen bee ingests only this royal jelly for life, and produces a huge number of eggs. This is because royal jelly has a rich nutritional and diverse physiological action, which is said to be a complete food. That is, this physiological action is an anticancer action, an antitumor action, a wound healing promoting action, an antibacterial action, an antidiabetic action, a blood flow increasing action, an anti-atherogenic action, a growth promoting action and the like. This means that the physiologically active substance is present in the royal jelly. Focusing on these points, royal jelly is used as health foods, cosmetics, pharmaceuticals, and the like.
【0007】動物細胞培養において、このようなローヤ
ルゼリー中の蛋白質画分を各種無血清培地に添加するこ
とにより、最良の増殖促進効果が得られる。即ち、ロー
ヤルゼリーから蛋白質を分離精製し、得られた蛋白質を
培地の量に対して0.1 μg /mlから4mg/mlの範囲で添
加すれば、効率的な各種細胞培養を行うことができる。
そして、生産物からの有用物質の分離も容易である。従
って、従来用いられてきた蛋白質性の成長促進因子、例
えばインシュリン、牛胎児血清、サイトカイン類等の蛋
白質成分を加えることなく、細胞培養を効果的に行うこ
とができる。In animal cell culture, the best growth promoting effect can be obtained by adding the protein fraction in such royal jelly to various serum-free media. That is, various proteins can be efficiently cultured by separating and purifying proteins from royal jelly and adding the obtained proteins in the range of 0.1 μg / ml to 4 mg / ml with respect to the amount of medium.
And, it is easy to separate the useful substance from the product. Therefore, the cell culture can be effectively performed without adding the conventionally used proteinaceous growth-promoting factors such as insulin, fetal bovine serum, and protein components such as cytokines.
【0008】ローヤルゼリー中の蛋白質、即ち増殖促進
活性を示す因子は以下のように容易に分離精製すること
ができる。即ち、常法により得られた蛋白質画分をゲル
濾過、イオン交換クロマトグラフィ、疎水性クロマトグ
ラフィ、電気泳動、逆相カラムクロマト等を用いた高速
液体クロマトグラフィ等の方法により高収率で分離精製
される。得られた蛋白質は、例えばイオン交換クロマト
グラフィで分画される。従って、得られたローヤルゼリ
ー由来の蛋白質は、従来の蛋白質性増殖因子よりも単一
のものが得られると共に、製造ロット毎の品質の差が少
なく、低コストで得られる。The protein in royal jelly, that is, the factor showing the growth promoting activity, can be easily separated and purified as follows. That is, the protein fraction obtained by a conventional method is separated and purified in a high yield by a method such as gel filtration, ion exchange chromatography, hydrophobic chromatography, electrophoresis, high performance liquid chromatography using reversed phase column chromatography and the like. The obtained protein is fractionated by, for example, ion exchange chromatography. Therefore, the obtained protein derived from royal jelly can be obtained as a single protein as compared with the conventional proteinaceous growth factors, and the quality difference between production lots is small, and the protein can be obtained at low cost.
【0009】このようにして、分画されたDI 画分、D
II画分、DIII 画分が得られる。これらの画分のうち、
DIII 画分が最も細胞の増殖促進能が高い。このDIII
画分は等電点が4.4 から5.4 であり、分子量(重量平均
分子量)4万から6万のサブユニット約6個からなる分
子量30万から40万の範囲の糖蛋白質画分である。こ
の糖蛋白質画分は透析後凍結乾燥によって粉末化し、4
℃以下で保存すれば数年間安定性があり、動物細胞増殖
促進作用が保持される。The DI fraction, D, thus fractionated
Fractions II and DIII are obtained. Of these fractions
The DIII fraction has the highest cell growth promoting ability. This DIII
The fraction is a glycoprotein fraction having an isoelectric point of 4.4 to 5.4 and a molecular weight of 300,000 to 400,000, which is composed of about 6 subunits having a molecular weight (weight average molecular weight) of 40,000 to 60,000. This glycoprotein fraction was dialyzed and lyophilized to give a powder.
If stored at or below ℃, it will be stable for several years, and the activity of promoting animal cell growth will be retained.
【0010】[0010]
【実施例】以下にこの発明を具体化した実施例について
図1,2を用いて説明する。 (実施例1、細胞増殖促進作用を有する糖蛋白質の製造
法)生ローヤルゼリー107gを50mMリン酸緩衝液
(pH6.2 )に混合して、透析即ち半透膜により低分子
化合物を除去し、分子量1万以上の蛋白質画分を得た。
この画分に対して、遠心分離(20000G、20分)
を行い、上清を得た。この上清を予め、上記リン酸緩衝
液で平衡化したイオン交換カラム(DEAE-TOYOPEARL 650
M )に通し、非吸着画分を溶出させた後、吸着画分を塩
化ナトリウムの濃度が0から0.3 Mとなるように直線的
に増加させて、溶出を行った。Embodiments Embodiments embodying the present invention will be described below with reference to FIGS. (Example 1, production method of glycoprotein having cell growth promoting action) 107 g of raw royal jelly was mixed with 50 mM phosphate buffer (pH 6.2), and low molecular weight compounds were removed by dialysis, that is, a semipermeable membrane to obtain a molecular weight. Over 10,000 protein fractions were obtained.
Centrifugation (20,000 G, 20 minutes) for this fraction
Was performed to obtain a supernatant. This supernatant was preliminarily equilibrated with the above-mentioned phosphate buffer solution using an ion exchange column (DEAE-TOYOPEARL 650
After elution of the non-adsorbed fraction, the adsorbed fraction was linearly increased to a sodium chloride concentration of 0 to 0.3 M for elution.
【0011】その結果、図1に示すように、DI 〜DII
I 画分が得られた。DI 画分は2.24g(蛋白質回収率3
1.4%)、DII画分は 0.2g(蛋白質回収率 2.8%)、
DIII画分は3.15g(蛋白質回収率44.2%)であった。
なお、イオン交換カラムにおける溶出条件は、次のよう
に設定した。As a result, as shown in FIG. 1, DI to DII
I fraction was obtained. DI fraction is 2.24 g (protein recovery rate 3
1.4%), DII fraction 0.2g (protein recovery rate 2.8%),
The DIII fraction was 3.15 g (protein recovery rate 44.2%).
The elution conditions in the ion exchange column were set as follows.
【0012】カラムサイズ:1.5cm ×38cm、流速:43.8
ml/hr 、緩衝液(開始):50mMリン酸ナトリウム緩衝液
(pH 6.2) (溶出):50mMリン酸ナトリウム緩衝液(pH
6.2) +0.3mM までの濃度のNaCl また、図1におけるフラクションNoは、1フラクション
No当り5.9ml である。 (試験例1、細胞増殖促進作用の測定法)細胞培養は以
下のように行った。増殖促進作用を調べるための培養細
胞にヒト単球細胞(U937)及びヒト肺癌特異的抗体
を産するヒト・ヒトハイブリドーマ(HB4C5)を使
用し、HB4C5細胞は無血清培養法に従い、アミノ
酸、塩、糖、ビタミンを含む無血清培地(eRDF培地
等、特開平4−51891号公報参照)にITES(イ
ンシュリン、トランスフェリン、エタノールアミン、亜
セレン酸ナトリウム)を加えた培地を用い、U937は
eRDF培地に必要に応じて5%FBS(牛胎児血清)
を添加した培地を用い、それぞれ5%CO2 、37℃で
培養することにより行った。Column size: 1.5 cm x 38 cm, flow rate: 43.8
ml / hr, buffer (start): 50 mM sodium phosphate buffer (pH 6.2) (elution): 50 mM sodium phosphate buffer (pH
6.2) NaCl at concentrations up to +0.3 mM In addition, fraction No. in Fig. 1 is 1 fraction
It is 5.9 ml per No. (Test Example 1, method for measuring cell growth promoting action) Cell culture was performed as follows. Human monocytic cells (U937) and human-human hybridomas (HB4C5) producing human lung cancer-specific antibodies were used as the cultured cells for examining the growth-promoting effect. A serum-free medium containing sugar and vitamins (eRDF medium, etc., see Japanese Patent Laid-Open No. 4-51891) with ITES (insulin, transferrin, ethanolamine, sodium selenite) is used, and U937 is required for the eRDF medium. 5% FBS (fetal bovine serum) according to
It was carried out by culturing at 37 ° C. in 5% CO 2 using the medium to which was added.
【0013】細胞増殖促進活性及び細胞成長因子活性の
有無は、ローヤルゼリー糖蛋白質の添加による生細胞数
の増加度合いにより判定した。生細胞数の測定は、MT
T〔3-4,5-Dimethylthiazol-2-yl)-2,5-Diphenyl Tetra
zolium Bromide〕−アッセイ法により行った。このMT
T−アッセイ法はScudieroらの方法(Cancer Research
48,4827,1988)を一部改変して行った。The presence or absence of cell growth promoting activity and cell growth factor activity was judged by the degree of increase in the number of viable cells due to the addition of royal jelly glycoprotein. The number of viable cells can be measured by MT
T [3-4,5-Dimethylthiazol-2-yl) -2,5-Diphenyl Tetra
zolium Bromide] -assay. This MT
The T-assay method is the method of Scudiero et al. (Cancer Research
48, 4827, 1988) with some modifications.
【0014】即ち、まず24穴プレートを用いて培養し
た細胞を110μl ずつ96穴プレートに分注し、MT
T試薬を20μl ずつ加えた。4〜5時間反応させた
後、遠心分離し、上清を除去した沈澱に100μl の0.
04規定塩酸を含むイソプロパノールを加え、540nmの
吸光度を測定することにより行った。 (試験例2、U937細胞増殖促進作用)ローヤルゼリ
ー由来のDI 画分、DII画分及びDIII 画分をそれぞれ
eRDF培地に対して0.1 μg /ml 〜 4mg/ml の範囲で
添加して無血清培地を得た。この培地を用いてU937
細胞に対しての培養を5日間行った。その結果を図2に
示す。図2に示すように、DIII 画分の生細胞数が最も
多く、最も良好な細胞増殖活性を示した。特に、DIII
画分の添加量が 2mg/ml のところでピークを示し、コン
トロール(培地としてeRDF培地に前記FBSのみを
添加した比較例)に比較して約7倍の増殖促進活性が見
られた。That is, first, cells cultured in a 24-well plate were dispensed in 110 μl aliquots into a 96-well plate, and MT
20 μl of T reagent was added. After reacting for 4 to 5 hours, the mixture was centrifuged and the supernatant was removed.
It was carried out by adding isopropanol containing 04N hydrochloric acid and measuring the absorbance at 540 nm. (Test Example 2, U937 cell growth promoting action) The serum-free medium was prepared by adding the royal jelly-derived DI fraction, DII fraction and DIII fraction to the eRDF medium in the range of 0.1 μg / ml to 4 mg / ml. Obtained. U937 using this medium
The cells were cultured for 5 days. The result is shown in FIG. As shown in FIG. 2, the number of viable cells in the DIII fraction was the highest, and the cell proliferation activity was the best. In particular, DIII
A peak appeared when the amount of the fraction added was 2 mg / ml, and about 7 times as much growth-promoting activity as that of the control (Comparative Example in which only FBS was added to the eRDF medium as a medium) was observed.
【0015】DIII 画分に次いでDII画分が高い細胞増
殖活性を示した。DI 画分は添加量が0.1 μg /ml 〜 1
mg/ml の範囲で細胞増殖活性を示した。また、図示はし
ないが、コントロールに対して細胞成長因子活性も発現
された。Following the DIII fraction, the DII fraction showed a high cell proliferation activity. Addition amount of DI fraction is 0.1 μg / ml 〜 1
It showed cell proliferation activity in the range of mg / ml. Although not shown, cell growth factor activity was also expressed in comparison with the control.
【0016】なお、この発明は上記実施例に限定される
ものではなく、発明の趣旨を逸脱しない範囲で例えば次
のように構成を変更して具体化してもよい。 (イ)ローヤルゼリー由来の蛋白質としてDI 画分又は
DII画分を、無血清培地に添加して細胞培養を行うこ
と。 (ロ)この発明を植物細胞の培養に適用すること。The present invention is not limited to the above-mentioned embodiments, but may be embodied by changing the structure as follows, for example, without departing from the spirit of the invention. (A) The cell culture is performed by adding the DI fraction or DII fraction as a protein derived from royal jelly to a serum-free medium. (B) Applying the present invention to culturing plant cells.
【0017】[0017]
【発明の効果】以上詳述したようにこの発明によれば、
優れた細胞増殖促進活性等の細胞培養活性を有して効率
的な細胞培養ができる共に、生産物の分離、精製を容易
に行うことができ、しかも低コストで安定した品質のも
のを供給できるという優れた効果を奏する。As described above in detail, according to the present invention,
Efficient cell culture can be performed with excellent cell growth promoting activity and other cell culture activities, product separation and purification can be easily performed, and stable quality products can be supplied at low cost. It has an excellent effect.
【図1】この発明の実施例におけるローヤルゼリー蛋白
質のフラクションNoと吸光度との関係を示すグラフで
ある。FIG. 1 is a graph showing the relationship between the fraction No. and the absorbance of royal jelly proteins in Examples of the present invention.
【図2】同じく実施例における蛋白質量と生細胞数との
関係を示すグラフである。FIG. 2 is a graph showing the relationship between the amount of protein and the number of viable cells in the same example.
Claims (1)
ことを特徴とする細胞培養のための無血清培地用添加組
成物。1. An additive composition for serum-free medium for cell culture, which comprises a protein derived from royal jelly.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4270531A JPH06113828A (en) | 1992-10-08 | 1992-10-08 | Additive composition for serum-free medium |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4270531A JPH06113828A (en) | 1992-10-08 | 1992-10-08 | Additive composition for serum-free medium |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH06113828A true JPH06113828A (en) | 1994-04-26 |
Family
ID=17487518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP4270531A Pending JPH06113828A (en) | 1992-10-08 | 1992-10-08 | Additive composition for serum-free medium |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH06113828A (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4844786B2 (en) * | 2000-02-15 | 2011-12-28 | 株式会社林原生物化学研究所 | Cell activator |
CN109608516A (en) * | 2019-01-23 | 2019-04-12 | 中国农业科学院蜜蜂研究所 | Rapid purification method of royal jelly major proteins 1, 2 and 3 |
-
1992
- 1992-10-08 JP JP4270531A patent/JPH06113828A/en active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4844786B2 (en) * | 2000-02-15 | 2011-12-28 | 株式会社林原生物化学研究所 | Cell activator |
CN109608516A (en) * | 2019-01-23 | 2019-04-12 | 中国农业科学院蜜蜂研究所 | Rapid purification method of royal jelly major proteins 1, 2 and 3 |
CN109608516B (en) * | 2019-01-23 | 2020-11-27 | 中国农业科学院蜜蜂研究所 | Rapid purification method of royal jelly major proteins 1, 2 and 3 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW516962B (en) | A human TNFR1-IgG1 preparation | |
US5500229A (en) | Colostrum fraction, a process of preparing it and its use as a supplement in cell culture media | |
US5428016A (en) | Antimicrobial peptide and antimicrobial agent | |
HU180566B (en) | Process for the microbiological production of l-threonine | |
US5317084A (en) | Process for large-scale production of antimicrobal peptide in high purity | |
US20220154239A1 (en) | Peptide for complexing zinc ion, complex thereof and use therefor | |
US20050209442A1 (en) | Method for high yield purification of immune globulins from blood plasma and blood plasma intermediates | |
RU2054044C1 (en) | Method of preparing human recombinant gamma-interferon without n-terminal methionine | |
JPS58192896A (en) | interferon | |
JPH06113828A (en) | Additive composition for serum-free medium | |
US5468635A (en) | In vitro method for stimulating cell growth by culturing cells in a serum-free culture medium comprising human lysozyme | |
Savelkoul et al. | Semi-preparative purification and validation of monoclonal antibodies for immunotherapy in mice | |
US4452893A (en) | Cell growth medium supplement | |
EP0366532B1 (en) | Medical preparations containing glycosylated interleukin-2 | |
CN115537442A (en) | Yolk phosphopeptide, and efficient enrichment preparation method and application thereof | |
JPH0432078B2 (en) | ||
CN1166688C (en) | Method of separating lactotransferrin from whey liquid | |
JP2947481B2 (en) | Antibody production promoting substance and antibody production method | |
CN102443055A (en) | Purification process of recombinant human tumor necrosis factor related apoptosis inducing ligand | |
JP2897043B2 (en) | Complete synthetic medium | |
Brown et al. | Applications of the mass culturing technique (MCT) in the large scale growth of mammalian cells | |
JPS59162880A (en) | Production of plasminogen activator | |
RU2183971C2 (en) | Method of immunoglobulin preparation preparing | |
CN1557939A (en) | Growth factor containing cell culture solution additive | |
KR920008378B1 (en) | Method for Purifying Human Insulin-like Growth Factor-I |